Shenzhen Antigen Detection Reagents are Temporarily Included in the Basic Medical Insurance

The National Medical Insurance Administration issued the "Notice of the Office of the National Medical Security Administration on Effectively Doing a Good Job in the Current Epidemic Prevention and Control Medical Security Work ", which mentioned that each provincial medical security department should follow the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 9)" " (hereinafter referred to as the "Diagnosis and Treatment Plan (Trial Version 9)") and the "New Coronavirus Pneumonia Prevention and Control Plan"; comprehensively considering the needs of epidemic prevention and control; and the payment capacity of the medical insurance fund in the region, according to scientific precision, active and stable, and risk control. The principle of timely adjustment and optimization of medical insurance-related policies.

1. According to the procedures, the new coronavirus antigen detection reagents and corresponding detection items are temporarily included in the catalogue of basic medical insurance medical service items in this province.

The relevant expenses incurred by the insured in the designated primary medical institutions shall be paid in accordance with the current regulations of the overall planning area, and the expenses of purchasing testing reagents at the designated retail pharmacies can be paid using personal accounts. All provincial medical security departments shall continue to standardize and optimize public medical institutions with reference to the "Letter of the Office of the National Medical Security Administration on Opinions on Local Proposed Temporary New Coronavirus Antigen Testing Items and Related Matters" (Medical Insurance Office Letter [2022] No. 11) Pricing policy for providing COVID-19 antigen testing services. Centralized pharmaceutical procurement agencies in various regions should do a good job in the online purchase of novel coronavirus antigen detection reagents, actively promote online purchases, and rely on the national unified medical insurance information platform for information sharing. At the same time, it will strengthen the calculation and monitoring, and coordinate the promotion of price, procurement, payment and information system transformation.

2. Timely adjustment of the new crown treatment drugs included in the scope of medical insurance payment.

For the newly added drugs in the "Diagnosis and Treatment Plan (Ninth Edition for Trial Implementation)", all provincial medical security departments refer to the "Notice of the National Medical Security Administration and the Ministry of Finance on Doing a Good Job in Medical Insurance for Pneumonia Infected by Novel Coronavirus" (National Medical Insurance [2020] ] No. 5), and temporarily include it in the payment scope of the medical insurance fund in the province; for the drugs that are transferred from the "Diagnosis and Treatment Plan (Trial Version 9)" and are not included in the basic medical insurance catalogue, each provincial medical security department should The medical insurance payment will be suspended from the date of the release of the Diagnosis and Treatment Plan (Trial Version 9). All provincial medical security departments should do a good job in the work of adding new drugs to the Internet. For drugs that have not been listed on the Internet, medical institutions are allowed to purchase offline first for emergency use. The newly added naimatevir tablets/ritonavir tablets in the "Diagnosis and Treatment Plan (Trial Version 9)" shall be purchased by medical institutions at the price agreed between the enterprise and relevant departments, and the medical insurance department shall pay according to regulations.

Reminder: Search the official account Shenzhen Local Treasure on WeChat, and reply to [Antigen] in the dialog box after following it to obtain the latest news such as the purchase method, product price, usage method, and precautions of the COVID-19 antigen detection kit.